Physician profile
John A Cox
NPI 1396763389
$2,101.11
in general payments reported to CMS, 2019-2025
29 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $171 · 2021: $218 · 2022: $485 · 2023: $95.87 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $362.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $278.26 | 2019-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $157.70 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $136.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.51 | 2021-2023 | Glassia |
| Fisher & Paykel Healthcare INC | $109.96 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.89 | 2019-2022 | |
| Grifols USA, LLC | $90.69 | 2019-2020 | |
| Philips North America LLC | $82.12 | 2022-2025 | Vest Therapy Und |
| Insmed, INC. | $75.94 | 2019-2025 | Arikayce |
| Exact Sciences Corporation | $65.10 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $64.26 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $48.59 | 2019-2021 | |
| Harmony Biosciences LLC | $42.50 | 2020-2022 | |
| Mylan Specialty L.P. | $41.23 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.06 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $38.13 | 2019 | |
| Insulet Corporation | $29.05 | 2021 | |
| Biomerieux INC | $25.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.25 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.34 | 2021 | |
| Genentech USA, INC. | $21.07 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.67 | 2020 | |
| United Therapeutics Corporation | $18.95 | 2021 | |
| Viatris Specialty LLC | $18.69 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $18.37 | 2019 | |
| Medtronic, INC. | $17.45 | 2023 | Intellis Adaptivestim |
| Verona Pharma, INC. | $14.12 | 2025 | Ohtuvayre |
| Abbott Laboratories | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.